Scynexis shares surge 16.95% intraday after completing BREXAFEMME NDA transfer to GSK, enabling FDA interactions and future royalties.

Scynexis (SCYX) surged 16.95% intraday after announcing the completion of the BREXAFEMME NDA transfer to GSK. This milestone enables GSK to initiate FDA discussions for the antifungal drug’s relaunch in the U.S., with Scynexis set to receive net sales milestones and royalties. The move signals regulatory progress and potential future revenue, aligning with the stock’s sharp intraday rally.